Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a ...

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

Q2 2025 Earnings Call Transcript July 31, 2025 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $1.46, expectations were $1.07. Operator: Good day, and welcome to the ...

Discover Bristol-Myers Squibb's Q2 2025 earnings insights: 17% growth, new partnerships, and raised guidance signal strong performance and a ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064. Taking into account the Volume and Open Interest on ...

World shares retreated Friday after President Donald Trump issued a new set of import duties that will apply to dozens of ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now. On July 31, the company reported results for Q2 2025, wherein it saw healthy momentum throughout its ...

Bristol Myers Squibb reported unexpectedly strong second-quarter results, driven by legacy products like Eliquis, despite ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.